Question 1

Should I switch from Saxenda to Zepbound?

Accepted Answer

For most adults, yes. Saxenda produced roughly 8% body-weight reduction in SCALE Obesity (Pi-Sunyer 2015 NEJM, PMID 26132939), whereas Zepbound delivered 20.9% TBWL at 72 weeks in SURMOUNT-1 (Jastreboff 2022 NEJM, PMID 35658024) — a nearly 3x larger effect. Zepbound is also once weekly rather than once daily and has a manufacturer cash-pay tier ($349-$499 via LillyDirect) that Saxenda does not match. Restart at Zepbound 2.5 mg regardless of prior Saxenda dose; expect a brief GI titration period. The main reasons to stay on Saxenda are adolescent use (12-17) or near-term pregnancy planning, where Saxenda's shorter washout is preferable.

Question 2

Why is Saxenda still prescribed if Zepbound is more effective?

Accepted Answer

Three niches keep Saxenda relevant. First, it is FDA-approved for adolescents 12 and older with BMI at or above the 95th percentile — Zepbound is adult-only. Second, liraglutide's short half-life (~13 hours) means a 1-day washout is sufficient before conception, vs roughly 6 days for tirzepatide; this matters when patients are actively trying to become pregnant. Third, some insurance formularies still place Saxenda on a lower tier than Zepbound, so step-therapy rules can require a Saxenda trial first. Outside these situations, Zepbound's larger effect size and weekly dosing usually win.

Question 3

Is daily injection a deal-breaker with Saxenda?

Accepted Answer

It is the most common reason patients ask to switch. Saxenda requires a once-daily subcutaneous injection — 365 injections per year vs roughly 52 for a weekly drug like Zepbound. Real-world adherence data show daily GLP-1s have meaningfully lower persistence at 12 months than weekly options. The daily schedule also means missed-dose recovery is more disruptive: skipping a Saxenda dose typically requires resuming the next day at the same dose without doubling up, while a missed Zepbound dose can usually be taken within 4 days of the scheduled day.

Question 4

Can my child use Zepbound?

Accepted Answer

Not yet. Zepbound is FDA-approved for adults 18 and older only. Saxenda is the only GLP-1 weight-loss medication currently approved for adolescents 12-17 with BMI at or above the 95th percentile for age and sex. Wegovy (semaglutide 2.4 mg) is also approved for ages 12 and older. A pediatric Zepbound trial (SURMOUNT-ADOLESCENTS) is ongoing but has not produced FDA-labeled pediatric indications as of 2026. For patients under 18 who need a GLP-1, the practical choice is between Saxenda (daily) and Wegovy (weekly).

Question 5

What about Saxenda's shorter washout for pregnancy planning?

Accepted Answer

Saxenda's roughly 1-day washout is a meaningful advantage for patients planning to conceive soon. Liraglutide's half-life is about 13 hours, so most clinicians recommend stopping 1-2 days before attempting conception. Tirzepatide's half-life is roughly 5 days, which translates to a 5-7 day washout window — and because tirzepatide can delay oral contraceptive absorption, additional barrier contraception is recommended during dose changes. Neither drug should be used during pregnancy. If pregnancy is months or years away, the washout difference does not matter much; if it is weeks away, Saxenda is the cleaner stop.

Question 6

Why is Saxenda so much more expensive without insurance?

Accepted Answer

Novo Nordisk has not launched a manufacturer cash-pay program for Saxenda comparable to LillyDirect's Zepbound tier ($349 starter / $499 maintenance) or NovoCare's Wegovy tier. Saxenda's US wholesale acquisition cost runs about $1,400/month and retail prices typically range $1,300-$1,500 cash. Commercial-insurance savings cards exist but exclude cash-pay, Medicare, and Medicaid patients. The pricing gap is one of the strongest practical reasons most uninsured adults choose Zepbound over Saxenda when both are clinically appropriate.

Field	Saxenda	Zepbound
Mechanism	GLP-1 receptor agonist (mono)	Dual GIP / GLP-1 receptor agonist
Pivotal weight-loss trial	−8.0% body weight / 56 wk (SCALE Obesity, 3.0 mg)	−20.9% TBWL / 72 wk (SURMOUNT-1, 15 mg)
Dosing frequency	Once-daily subcutaneous injection (5-step titration to 3.0 mg)	Once-weekly subcutaneous injection (6-step titration to 15 mg)
FDA-approved indications	Chronic weight management in adults; adolescents 12-17 with BMI ≥95th percentile	Chronic weight management (adults); moderate-to-severe obstructive sleep apnea (adults)
Pediatric availability	Approved for ages 12 and older	Adult-only (18+)
Cardiovascular outcome	No dedicated obesity CVOT (LEADER tested T2D-dose liraglutide 1.8 mg, not 3.0 mg)	SURPASS-CVOT readout pending 2027
Half-life and washout	~13 hours; ~1-day washout (useful for pre-pregnancy planning)	~5 days; ~6-day washout window pre-conception
Cash price (manufacturer direct)	No manufacturer cash-pay program; ~$1,400/mo retail	$349-$499/mo via LillyDirect (vials)

Saxenda vs Zepbound (2026): Daily Liraglutide vs Weekly Tirzepatide

The verdict

Side-by-side comparison

Frequently asked questions